journal article·2017-04-03Open access

Application of quality-by-design approach to optimize diallyl disulfide-loaded solid lipid nanoparticles

Siddhartha Venkata Talluri, Gowthamarajan Kuppusamy, Veera Venkata Satyanarayana Reddy Karri, Karthik Yamjala, Ashish Wadhwani, SubbaRao V. Madhunapantula, Saikiran S. S. Pindiprolu

Abstract

The current work was carried out by the principles of quality-by-design approach to develop an optimized solid lipid nanoparticles (SLNs) formulation of diallyl disulfide (DADS) through systematic statistical study. And its antitumor activity of DADS was also evaluated on breast cancer cell lines. To understand the effect of formulation variables (critical parameters) on the responses (critical quality attributes) of SLN, a 3-factor, 3-level Box-Behnken design, was explored to predict the responses such as particle size (Y1) and % entrapment efficiency (EE) (Y2) when concentration of surfactant (X1), amount of lipid (X2), and volume of solvent (X3) were selected as independent variables. Particle size analysis revealed that all the batches were within the nanometer range. DADS was released from the SLN much more rapidly at pH 4.5 than at pH 7.4, which is a desirable characteristic for tumor-targeted drug delivery. The cytotoxicity, reactive oxygen species (ROS), determination revealed that the antitumor activity of DADS is enhanced with SLN compared to DADS-free drug, and apoptosis is the mechanism underlying the cytotoxicity. The present study indicated the remarkable potential of DADS-SLN in enhancing the anticancer effect of DADS in breast cancer cells in vitro.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Garlic and Onion Studies · Advancements in Transdermal Drug Delivery · Essential Oils and Antimicrobial Activity

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Udhagamandalam, Tamil Nadu, India;

Department of Pharmaceutical Analysis, JSS College of Pharmacy, JSS University, Udhagamandalam, Tamil Nadu, India;

Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS University, Udhagamandalam, Tamil Nadu, India;

Department of Biochemistry, JSS Medical College, JSS University, Mysore, Karnataka, India;

Department of Pharmacology, JSS College of Pharmacy, JSS University, Udhagamandalam, Tamil Nadu, India

References (50)

Show source-provided references
1. 10.1016/S1286-4579(99)80003-310.1016/S1286-4579(99)80003-3 ↗
2. 10.1080/00401706.1960.1048991210.1080/00401706.1960.10489912 ↗
3. Cho HJ · Int J Nanomed · 2014 · 9 · 495
4. 10.1016/j.ejpb.2006.09.00110.1016/j.ejpb.2006.09.001 ↗
5. 10.1093/carcin/bgh12310.1093/carcin/bgh123 ↗
6. 10.1016/j.toxlet.2012.10.00810.1016/j.toxlet.2012.10.008 ↗
7. Gambhire M · Curr Pharm Res · 2011 · 1 · 15710.33786/JCPR.2011.v01i02.012 ↗
8. 10.3109/1061186X.2014.96571710.3109/1061186X.2014.965717 ↗
9. 10.1080/004982502100001790210.1080/0049825021000017902 ↗
10. 10.1186/2008-2231-21-6810.1186/2008-2231-21-68 ↗
11. 10.3109/21691401.2014.97146210.3109/21691401.2014.971462 ↗
12. 10.1111/j.1742-4658.2009.07329.x10.1111/j.1742-4658.2009.07329.x ↗
13. 10.1016/S0168-3659(97)00102-810.1016/S0168-3659(97)00102-8 ↗
14. Guideline IHT. 2009. Pharmaceutical Development Q8 (R2). ICH Steering Committee Current Step 4.
15. Hao J · Int J Nanomedicine · 2011 · 6 · 683
16. 10.1038/emm.2000.2210.1038/emm.2000.22 ↗
17. 10.1016/j.colsurfb.2005.08.00510.1016/j.colsurfb.2005.08.005 ↗
18. 10.3109/10717544.2014.91867710.3109/10717544.2014.918677 ↗
19. Knowles LM · J Nutr. · 2001 · 131 · 1061S10.1093/jn/131.3.1061S ↗
20. 10.1055/s-2006-95997610.1055/s-2006-959976 ↗
21. 10.4174/jkss.2011.81.2.8510.4174/jkss.2011.81.2.85 ↗
22. 10.1111/j.1745-7254.2008.00851.x10.1111/j.1745-7254.2008.00851.x ↗
23. 10.1046/j.1365-2672.2002.01707.x10.1046/j.1365-2672.2002.01707.x ↗
24. Liao QJ · Ai Zheng · 2009 · 28 · 138
25. 10.1016/j.colsurfa.2009.11.00610.1016/j.colsurfa.2009.11.006 ↗
26. 10.3109/0363904090346045310.3109/03639040903460453 ↗
27. 10.3109/10837450.2014.88293510.3109/10837450.2014.882935 ↗
28. 10.1016/S0939-6411(00)00087-410.1016/S0939-6411(00)00087-4 ↗
29. 10.1016/j.bcp.2012.08.02410.1016/j.bcp.2012.08.024 ↗
30. 10.1088/0957-4484/22/49/49400210.1088/0957-4484/22/49/494002 ↗
31. 10.1016/j.ejpb.2011.03.02210.1016/j.ejpb.2011.03.022 ↗
32. 10.1002/ijc.2381810.1002/ijc.23818 ↗
33. 10.1016/S0939-6411(02)00130-310.1016/S0939-6411(02)00130-3 ↗
34. 10.1016/S0165-0270(98)00147-210.1016/S0165-0270(98)00147-2 ↗
35. Sengupta A · Asian Pac J Cancer Prev · 2004 · 5 · 237
36. 10.1007/s11095-014-1504-210.1007/s11095-014-1504-2 ↗
37. 10.3923/ajdd.2011.174.18710.3923/ajdd.2011.174.187 ↗
38. 10.1038/nrm295210.1038/nrm2952 ↗
39. Vaupel P · Cancer Res · 1989 · 49 · 6449
40. 10.2174/156720181166614041411525910.2174/1567201811666140414115259 ↗
41. 10.1038/nprot.2006.17910.1038/nprot.2006.179 ↗
42. 10.1016/j.ijbiomac.2014.01.05410.1016/j.ijbiomac.2014.01.054 ↗
43. 10.1016/S0891-5849(99)00107-010.1016/S0891-5849(99)00107-0 ↗
44. 10.1016/j.addr.2003.12.00210.1016/j.addr.2003.12.002 ↗
45. 10.1016/j.mrfmmm.2005.02.02610.1016/j.mrfmmm.2005.02.026 ↗
46. 10.1016/j.nano.2009.05.00410.1016/j.nano.2009.05.004 ↗
47. Yang JS · Anticancer Res · 2006 · 26 · 219
48. 10.3748/wjg.v10.i18.273110.3748/wjg.v10.i18.2731 ↗
49. 10.1038/sj.cdd.440084310.1038/sj.cdd.4400843 ↗
50. Zhang L · Int J Nanomedicine · 2015 · 10 · 2101